USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
02 Sep 2021 | 01:45 PM GMT

Best routes to market for Remote Patient Monitoring companies

Anchored by:

Don Deyo
Chief Executive Officer
LINDACARE
Sharon Baer
Portfolio Marketing Leader
KONINKLIJKE PHILIPS

Participants:

Don Deyo Chief Executive OfficerLindaCare
Don Deyo
Chief Executive OfficerLindaCare
Sharon Baer Portfolio Marketing LeaderKoninklijke Philips
Sharon Baer
Portfolio Marketing LeaderKoninklijke Philips
Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
Chris Henderson Global Sr Director Digital HealthSmith + Nephew
Chris Henderson
Global Sr Director Digital HealthSmith + Nephew
Claire Donnelly Head of Medical PartnershipsHappitech
Claire Donnelly
Head of Medical PartnershipsHappitech
Dr. Nick (Nemanja) Kovacev Head of Healthcare and Life Sciences PracticeHTEC Group
Dr. Nick (Nemanja) Kovacev
Head of Healthcare and Life Sciences PracticeHTEC Group
Ivan Jurisic Head of ProductPatients Influence
Ivan Jurisic
Head of ProductPatients Influence
Jin Lee Director of Digital HealthAstellas Pharma, Inc
Jin Lee
Director of Digital HealthAstellas Pharma, Inc
Kris Karson SVP, Corporate DevelopmentAtropos Health
Kris Karson
SVP, Corporate DevelopmentAtropos Health
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Nader Alaghband Co-Founder & CEOAmpersand Health
Nader Alaghband
Co-Founder & CEOAmpersand Health
Richie Bavasso PresidentPneumoWave
Richie Bavasso
PresidentPneumoWave
Suraj Shah InvestorNorwest Venture Partners
Suraj Shah
InvestorNorwest Venture Partners

About this Meeting

What are the best routes to market for Remote Patient Monitoring (RPM) companies? A survey from 2020 suggested that 55 to 58% of the European physicians believe that Remote Patient Monitoring (RPM) will play a key role in the future of care. But in order to successfully gain adoption, RPM companies need to figure out what is the most sustainable and scalable route to market. Join us in this informal conversation with other senior leaders where we will discuss: 

  •  What are the most scalable and sustainable commercialization models for RPM (e.g partnerships with payers, employers, pharma, medtech, hospitals, D2C, etc)? 
  • Keys to success? Factors that determine the best route to market (e.g geographies, disease, objective of the program -prevention, diagnosis, management, etc-, others) 
  •  Implications of choosing one route to market vs. others (evidence requirements, pricing strategies, organization structure of the company, etc)